Retigabine
MHRA Drug Safety Update May 2017
MHRA Drug Safety Update May 2017 A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (vol 10, […]
Retigabine (Trobalt®) product withdrawal
Retigabine (Trobalt®) is to be withdrawn from the market in June 2017. This product is being discontinued because of limited and declining use. A letter for healthcare professionals outlines advice for healthcare providers to begin seeking alternative treatment for affected patients, and to withdraw treatment with a gradual dose reduction over at least 3 weeks. No new patients should start retigabine treatment.